CFDE Data Portal | Search CYP1B1-AS1

	Label	Description
	CYP1B1-AS1 associations Collection (Entity type)	Associations for CYP1B1-AS1_associations
	CYP1B1-AS1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	CYP1B1-AS1 Gene (Entity type)	ENSG00000232973 - CYP1B1 antisense RNA 1
	GSE240439 decitabine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 6 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE138789 metformin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE226285 3 V 0 GLUTATHIONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE152441,GSE152442 6 V 4 FOLIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

CYP1B1-AS1 associations

Associations for CYP1B1-AS1_associations

CYP1B1-AS1 associations.tsv

A file from IDG as part of the Harmonizome project

CYP1B1-AS1

ENSG00000232973 - CYP1B1 antisense RNA 1

GSE240439 decitabine 1 v 2 human up

A Gene Set from LINCS

GSE239844 crizotinib 6 v 9 human up

A Gene Set from LINCS

GSE226249 pirfenidone HL 2 v 1 human up

A Gene Set from LINCS

GSE138789 metformin 0 v 1 human up

A Gene Set from LINCS

GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn

A Gene Set from LINCS

GSE226285 3 V 0 GLUTATHIONE HUMAN UP

A Gene Set from LINCS

GSE152441,GSE152442 6 V 4 FOLIC ACID HUMAN UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.